News | October 04, 2025
Supriya Lifescience’s Ambernath facility receives WHO GMP certification
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity
This investment will help BSV avoid carbon dioxide emissions by as much as 6560 tonnes of carbon dioxide equivalent (tCO2e) annually over its project life of 25 years
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Subscribe To Our Newsletter & Stay Updated
